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ABSTRACT
Endometrial carcinoma (EC) is the most common malignancy of the female genital tract encountered in western countries, 
making it the fourth most common cancer in women. The incidence of uterine cancer is on the rise throughout the de-
veloped world where diagnosis is increasingly observed among younger patients. With regard to this, attention has been 
focused on conducting more studies to achieve a better understanding of the molecular genetics related to endometrial 
carcinogenesis. Over the years, EC has been classified into two broad histopathological subtypes based on the mechanism of 
development, and we can therefore observe specific biomarkers related to the respective subtype. Based on this idea, more 
research has been carried out in the last decade, using biotechnological methods, with the aim to identify new potential 
tumor markers. By translating these findings into clinical use one may facilitate accurate diagnosis and prognostic predic-
tion, and contribute to individualized treatment. Without a doubt, there is a demanding need to identify biomarkers that 
can be adopted in clinical practice in order to reduce the time needed to obtain diagnosis. Such markers may be of great 
value in improving patient outcome. However, a number of problems remain to be solved before this becomes a reality. 
This paper briefly reviews the current status of rising biomarkers in EC.
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INTRODUCTION
Endometrial cancer (EC) is the most frequent type of 
gynaecological malignancy in developed countries [1]. The 
diagnosis is commonly observed among postmenopau-
sal women that seek medical attention following initial 
presentation of atypical vaginal bleeding prior, during or 
after menopause. Despite being one of the most common 
gynaecological malignancies, routine screening is not rec-
ommended as majority present with an early stage dis-
ease (stage I or II) resulting in favourable prognosis and 
excellent survival rate (5-year overall survival 75–90%) [2]. 
However, women encountering more advanced or recur-
rent disease will have an extremely poor clinical outcome. 
Thus, renewed research focus on better understanding the 
molecular changes associated with EC, which is mainly pro-
moted by the dramatic increase in incidence observed in 
the recent years [3]. In contrast to cervical cancer, there is 
still insufficient evidence to recommend any cost-effective 
screening method in women with average to high risk and 
without symptom presentation [1]. However, papanicolaou 
(Pap) smear, tranvaginal ultrasound, and endometrial sam-
pling are techniques under investigation for their ability to 
reveal EC at an early stage [4]. For the same purpose, differ-
ent molecular techniques have been applied in the search 
for markers that can be associated with EC stag, prognosis, 
and therapeutic response. Therefore, the aim of this paper 
is to briefly outline a panel of promising biomarkers that 
can be adopted as serum screening in cancer detection and 
prediction of outcome.
BIOMARKERS RELATED TO 
HISTOPATHOLOGICAL SUBTYPES OF EC
Based on the mechanism of development, we distinguish 
between two broad clinicopathological variants. Type I (en-
dometrioid) cancers comprise the large majority (70–80%) 
and is know to be estrogen-responsive. This subtype is as-
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sociated with unopposed estrogen stimulation and is more 
frequently observed among perimenopausal middle-aged 
women [2]. By contrast, type II (non-endometrioid cancer) 
follows the estrogen-unrelated pathway, which seems to arise 
from a background of atrophic endometrium. Type II tumors 
are commonly diagnosed in older postmenopausal women, 
and are generally less differentiated accounting for a poor 
prognostic outcome [2, 3]. A wide variety of proposed bio-
markers have been examined for EC of the respective subtype. 
Defects in DNA mismatch repair genes, microsatellite insta-
bility, and mutations in the PTEN and K-ras and/or B-catenin 
genes are mutated in high rates for type I, whereas alteration 
in the p53 suppressor gene with mutation of Her-2/neu are 
commonly observed in type II [2, 3]. Based on the significantly 
different gene expression profile, one can suspect that the 
two types may have distinct underlying etiologies, which in 
turn is responsible for the pathogenesis and progression [3]. 
For that reason, these biomarkers are currently used as dia- 
gnostic clues representing the most common basis for prog-
nostic estimation of this gynaecological malignancy [2].
ESTABLISHED MOLECULAR PROFILING 
TECHNIQUES 
Array-based technology
This is a well-established method for the investiga-
tion of gene expression in organs or tissues undergoing 
pathological changes [5]. Several studies have used array 
analysis to investigate genomic features of EC, resulting in 
detection of a large range of molecular alterations. To illus-
trate, Xue-Lian and colleagues performed oligonucleotide 
microarray to examine the global expression pattern of 
tumor-associated endothelial cells from EC [6]. The study 
was able to identify a consistent overexpression of certain 
marker genes in addition to loss of several tumor suppressor 
activities associated with EC. 
Meanwhile, in a different article, cDNA microarray was 
applied in the investigation of expression profiles for genes 
encoding extracellular matrix (ECM) proteins by compar-
ing level of markers in early and advanced stage of EC [7]. 
Initially, the authors presented an overexpression of six dif-
ferent ECM components shown to play an important role in 
the carcinogenesis of EC; aggrecan, collagen type VIII chain 
α1, collagen type XI chain α2, vitronectin, nidogen, and 
tenascin R. Gene microarray have attracted wide attention 
because of its ability to investigated hundreds to thousands 
of genes in parallel providing unique information about 
the expression of different genes related to EC [8]. Thus, 
becoming an important analytical tool in cancer research 
and clinical diagnostics.
Next-generation sequencing (NGS)
In a paper published by Creighton et al. a panel of novel 
miRNAs were discovered in the female reproductive organs 
using next-generation sequencing (NGS) technique (Tab. 1). 
Similarly, by performing whole-exome sequencing, Liang 
and colleges were able to identified 12 potential cancer 
genes. However, AT-rich interactive domain 1A (ARID1A) was 
the gene attracting most attention because of its suggested 
role in suppressing cell proliferation of ovarian and endome-
trial cancer cell lines [9]. The recent introduction of sequenc-
ing technology have aided in the discovery of new RNA 
molecules while providing more detailed understanding 
Table 1. Novel miRNAs in the female reproductive organs
miRNA Expression level Potential clinical role References
miR-200 family Up-regulated Mostly pronounced in early phase EEC 20, 21, 22
miR-205 and miR-210 Up-regulated Potential biomarkers for early diagnosis and prognosis of EC 22
miR-185, miR-106a, miR-181a, miR-210, 
miR-423, miR-103, miR-107, miR-let 7c Up-regulated
Transition from normal endometrium through atypical 
hyperplasia to cancer. No association between the expression 
level and cancer stage/grade
23
miR-77 family Up-regulated Clinically advanced tumors 22
hsa-miR-196a-5p, hsa-miR-328-3p, hsa-
miR-337-3p, and hsa- miR- 181c-3p Deregulated Potential diagnostic markers of EC 18
miR-let 7i, miR-221, miR-193, miR-152, 
miR-30c Decreased expression
Transition from normal endometrium through atypical 
hyperplasia to cancer. No association between the expression 
level and cancer stage/grade
23
miR-92a, miR-96, miR-200a, miR-203, 
miR-429, miR-449a Dysregulation FIGO staging 21
miR-200b*, miR-429, miR-9, miR-92, 
miR-449a Dysregulation Histological grading 21
miR-96, miR-183, miR-449a Dysregulation Cancer relapse 21
miR-203, miR-429 Dysregulation Lymph node metastasis 21
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of biological pathways related to endometrial tumorigene-
sis [10]. Compared with traditional microarrays, which can only 
detect a limited number of miRNA, NGS enables in-depth 
characterization of the global range of miRNAs [10, 11]. 
Also, it is suggested that genomic analysis of cells collected 
during Pap smears holds promise for early detection of EC 
[4, 10]. Thus, genome-wide studies using NGS can provide 
insight into the genomic alteration in association to EC.
Proteomics
Microarray and NGS studies have both provided unique 
information related to gene expression profile in EC, how- 
ever, information at a protein level is crucial in order to 
include post-translational events [7]. In several papers, pro-
teomics has been used to assess the clinical utility of bio-
markers to evaluate their diagnostic and prognostic sensiti- 
vity and specificity by comparing protein profiles between 
pathological and normal tissue. It is belived that proteins are 
directly linked to the phenotype and the malignant nature 
of cancer, which explain the increased interest for studying 
global protein expression [11]. A study performed by Li et al. 
exemplifies the value of proteomics where three potential 
EC-associated proteins were identified; Cyclophilin A (CypA), 
epidermal fatty acid-binding protein (E-FABP), and caclypho-
sine (CAPS) [11]. Additionally, increase in both E-FABP and 
CAPS in relation to EC were also reported in a different pa-
per [12]. Implementing this method, both papers conclude 
that the overexpression of E-FABP and CAPS is correlated 
to histodifferentiation but not to clinical staging [11, 12]. 
As identified by plasma membrane proteomics tech-
nique, an overexpression of bone marrow stromal anti-
gen 2 (BST2) was demonstrated in EC at both mRNA and 
protein level. Based on this finding, it was proposed that 
BST2 might have a suppressor effect on tumor growth by 
either blocking the function of target signalling molecules 
or receptors, or by stimulating apoptosis. For that reason, 
it is suggested that BST2 might have a potential value as 
a molecular therapeutic target [13]. Lastly, Maxwell et al. 
performed global differential proteomic to identify the 
level of proteins associated with in stage I EC [14]. Interest-
ingly, an overexpression of specific ribosomal proteins (RS3, 
RS9, RS14, RS18, RLA1, RLA2, RL8, RL11, RL22, RL18, RL24, 
RL10A, RL27A), which has not been previously described 
in acquaintance to EC, was established in this report. More 
importantly, a deregulation was found to include the follow-
ing set of proteins; (1) multiple members of peroxiredoxin 
family (PRDX1, PRDX3, PRDX4, PRDX5, PRDX6), (2) prohibitin 2 
(PHB2), and (3) members of the annexin family (ANXA1, 
ANXA2). As demonstrated by the abovementioned findings, 
we can emphasise that proteomic is an innovative approach 
for the identification of proteins and biomarkers that can be 
clinically adopted for diagnosis of EC [14]. 
BIOMARKERS WITH DIAGNOSTIC, 
PROGNOSTIC AND THERAPEUTIC VALUE IN EC
Astrocyte elevated gene-1 (AEG-1/MTDH/LYRIC)
While some papers are primarily focusing on further 
investigation of the already known set of genetic alterations, 
others are aiming to detect newer cancer genes (Tab. 2). The 
comprehensive list of novel biomarkers related to EC includes 
the recent discovery of Astrocyte elevated gene-1. AEG-1 is 
located at chromosome 8q22 [15] and is also known as 
metadherin (MTDH) and lysine-rich CEACAM1 coisolated 
(LYRIC) [17]. Since its discovery in 2002, as HIV- and TNF-
-α-inducible gene in primary human fetal astrocytes [15], 
several authors have described its tumor-promoting activity 
which is related to the activation of diverse signal transduc-
tion pathways (PI3K/ AKT, NF-κB, MEK/ERK, WNT/β-catenin) 
involved in cancer progression, in addition to its role in 
pathogenesis, metastasis, invasion, angiogenesis and over-
all patient survival [16]. It should be noticed that AEG-1 is 
an important oncogene were its expression status is firmly 
established in a subsequent array of cancers. 
More importantly, AEG-1 has been described to play 
a central role in carcinogenesis and progression of endo-
metrial cancer in a study conducted by Song et al. [17]. The 
expression rate of AEG-1 was investigated in 35 normal 
endometrial tissue, 40 atypical hyperplasia, and 174 EC 
tissue (161 cases being endometrioid carcinoma) show-
ing a gradual elevation with the transition from normal to 
cancerous tissue. Thus, AEG-1 was found to be significantly 
correlated with clinicopathological parameters includ-
ing FIGO stage (p < 0.001), depth of myometrial invasion 
(p = 0.015), lymph node metastasis (p = 0.005), lymph vas-
cular space invasion (p < 0.001), recurrence (p < 0.001), and 
Ki-67 expression (p = 0.032). Several authors have implied 
that an up-regulation of AEG-1 enhances characteristics 
of malignant aggressiveness making it an independent 
prognostic factor for unfavourable clinical outcome. This 
suggests that AEG-1 is valuable as a prognostic biomarker of 
disease progression and survival in patients with EC [16–18]. 
MicroRNAs
Since the discovery of microRNA (miRNA), several authors 
have been intensively studying their role as diagnostic and 
prognostic markers, and predictors of drug response. MiRNA 
have aroused wide attention because of their suggested 
role as important regulators of gene expression in a broad 
spectrum of diseases, including solid and hematologic ma-
lignancies [18]. This is a family of small (21–22 nucleotides) 
non-protein-coding RNAs responsible for messenger-RNA 
(mRNA) stability and expression of proteins at a post-tran-
scriptional level [18, 19]. For that reason, miRNAs has become 
well-established group of markers for the development and 
progression in a wide range of malignancies. In general, 
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miRNAs may either act as oncogenes or tumor suppres-
sors presenting increased or decreased expression in tumor 
cells [19]. This alteration in miRNA expression may be involved 
in the initiation, cancer progression, and metastatic process 
in different cancer types. In the course of EC, a study done 
by Tsukamoto et al. suggest that miRNAs are predominantly 
involved in cell proliferation, differentiation, apoptosis, and 
carcinogenesis of endometrium [19]. Because 118 differently 
expressed miRNAs associated to EC have been reported so 
far, clinically important miRNAs that contribute in the cancer 
progression has to be identified [20]. 
During the past decade, several miRNAs including 
hsa-miR-503, hsa-miR-205, and hsa-miR-200b were shown 
to be dysregulated in endometrioid endometrial carcino-
mas (EEC) [19, 20]. Moreover, a comparison of EC tissue to 
normal tissue control detected an up-regulation of miR-200 
family, which contains five miRNAs localized in two 
genomic clusters, chromosome 1 and 12 [20]. Correspond-
ing with these findings Torres et al. reported a significant 
up-regulation of all miR-200 family members, mostly pro-
nounced in the early phase of EEC [21]. Additionally, an over 
expression was found to encounter miR-205 and miR-210, 
suggesting them to be selected as biomarkers for the early 
diagnosis and prognosis of EC [22]. Xiong and colleges stud-
ied miRNAs in relation to early stage (stage I) EEC, and iden-
tified a deregulation of hsa-miR-196a-5p, hsa-miR-328-3p, 
hsa-miR-337-3p, and hsa-miR-181c-3p indicating their clini-
cal value as potential diagnostic markers [18]. By comparing 
gene expression patterns in normal endometrium, atypical 
hyperplasia and EC tissue, Boren et al. described a total of 
13 miRNAs that demonstrated a significance difference in 
level of expression [23]. In the transition from normal endo-
metrium through atypical hyperplasia to cancer, five miRNAs 
(miR-let 7i, miR-221, miR-193, miR-152, miR-30c) exhib-
ited a decrease in expression, leaving the remaining eight 
miRNAs (miR-185, miR-106a, miR-181a, miR-210, miR-423, 
miR-103, miR-107, miR-let 7c) with a relative increase in 
expression. Initially, there were no association between 
the miRNA expression and cancer stage or grade [23]. In 
another study aiming to investigate the clinical and patho-
logical characteristics, a set of miRNAs was found to be 
dysregulated in regards to FIGO staging (miR-92a, miR-96, 
miR-200a, miR-203, miR-429, miR-449a), histological grade 
(miR-200b*, miR-429, miR-9, miR-92, miR-449a) occurrence 
of relapse (miR-96, miR-183, miR-449a), and lymph node 
metastasis (miR-203, miR-429) [21]. Additionally, an over-
expression of miR-77 family was contributed to clinically 
more advanced tumors. The set of miRNAs presented in 
this paragraph were all identified by means of microar-
ray technology and/or next-generation sequencing (NGS) 
with further conformation using qRT-PCR. To investigate 
miRNA profiles, both plasma and tissue were collected 
form patients with EEC revealing their potential as future 
noninvasive biomarkers for early detection, diagnosis and 
prognosis of EC [18, 21]. Finally, it is suggested that miRNA 
can aid as potential therapeutic target by either blocking 
or mimicking the miRNA activity, however, further research 
need to be carried out [22, 23]. 
Table 2. The most significant molecular markers in EC detection
Biomarkers Normal endometrium
Atypical 
hyperplasia EC
Association with 
prognosis? References
Extracellular matrix (ECM) proteins (aggrecan, 
collagen type VIII chain α1, collagen type XI 
chain α2, vitronectin, nidogen, tensacin R)
No expression No expression High expression in stage III Yes 7
Epidermal fatty acid-binding protein (E-FABP) Weakly positive (79.5 %)
Weakly to strongly 
positive (100%)
Significantly 
stronger (100%) No 11
Caclyphosine (CAPS) Weakly positive (76.9 %)
Weakly to 
moderately 
positive (91.3%)
Significantly 
stronger (100%)
Yes (correlated 
with poor 
survival)
11
Bone marrow stromal antigen 2 (BST2) No detectable expression
Significantly 
overexpressed 
(up to 10-fold) 
No 13
Astrocyte elevated gene-1 (AGE-1) Weak or no expression Gradually elevated High expression Yes 17
Cyclophilin A (CypA) Weak or no expression
Up-regulated 
27.23-fold
Yes, but further 
studies need to 
be conducted
12
Human epididymis protein 4 (HE4) Weak or no expression Gradually elevated
Strongly 
expressed Yes 29
Matriptase (MT-SP1) Strongly expressed Yes 32
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Cyclophilin A (CYPA)
CypA is among the proteins that have been repeatedly 
reported to be involved in pathogenesis of several diseases 
including cancer, cardiovascular disease, and viral infec-
tions. This is a cytosolic binding protein that belongs to the 
immunophilin family, which are found in all prokaryotes 
and eukaryotes and is belived to have an important role 
in regulating protein folding process, T-cell activation, dif-
ferentiation, cell migration, proliferation, and Bcl-2 expres-
sion in various cells [24]. Research confirm its involvement 
in several types of cancer, were an up-regulation is belived 
to be correlated with poor outcome of the patients [25]. To 
date, only one proteomic study on CypA has been reported 
which presented an overexpression of CypA in EC based on 
individual-matched cancer specimen and normal endome-
trial tissue. Among 99 proteins identified, CypA was found 
to be one of the most significantly overexpressed protein 
in all EC tissues examined. Perhaps the clinically proved 
up-regulation of CypA in EC may be applied as an independ-
ent predictor of survival. Its potential value as a biomarker 
for prognosis and clinical treatment is supported by a selec-
tion of criteria, which include involvement and overexpres-
sion in EC, significant difference between EC specimen and 
control tissue, and its identification by mass spectrometry [26]. 
However, the precise role of CypA in targeted treatment of 
endometrial cancer remains to be established. 
Complementary to this, other studies have also aimed 
to investigate CypA as a potential marker in different cancer 
types. The results of those studies were similar and the CypA 
overexpression was shown to be significantly more likely to 
present with poor differentiation and decreased survival. 
Human epididymis protein 4 (HE4)
In gynaecological malignancies, HE4 have merged as 
a promising biomarker and was first described by Kirch-
hoff et al. by means of cDNA screening. This protein is also 
known as Whey acidic protein (WFCD2) localized on hu-
man chromosome 20q12-13.1 and is identified as one of four 
cDNAs highly expressed in the epididymis, trachea, lung, 
prostate, endometrium and breast [27]. In 2001, the United 
States Food and Drug Agency (FDA) approved this protein 
for monitoring of recurrence and progression in epithelial 
ovarian cancer. Because EC possesses many similarities to 
ovarian cancer it was desirable to investigate HE4 and its 
relations to EC. Brennan et al. performed a large popula-
tion-based cohort study to evaluate if serum HE4 can offer 
preliminary pre-operative risk stratification for EC. Specifi-
cally because of the high expression level of HE4 in EC tissue, 
and the increased serum level in this group of patients [28, 
29]. The result strongly implied that serum HE4 was an inde-
pendent poor prognostic marker, and it was suggested to 
use HE4 serum assay as a cost-effective approach to avoid 
unnecessary lymphadenectomy in patients with low risk 
EC. In a different paper the expression of HE4 in EC and its 
relations to clinicopathological parameters and prognosis of 
EC was studied. The goal was to detect the expression rate 
of HE4, by means of immunohistochemical using strepta-
vidin-peroxidase, in EC, endometrial atypical hyperplasia, 
and normal endometrial tissue samples, respectively [27, 
29]. The results implied that the intensity of HE4 expression 
increased with degree of malignancy. Thus, the level of 
HE4 in EC was significantly higher than that of hyperplasia 
and normal endometrium. Furthermore, the investigation 
showed no relations of HE4 to the pathological subtype but 
rather a strong relation to other factors like cancer stage, 
metastasis, myometrial invasion depth, recurrence, degree 
of differentiation and the overall survival rate. However, in 
another paper there was a lack of evidence to estimate the 
clinical value and to support the application of HE4 in EC [30]. 
In conclusion, further researches have to be carried out in 
order to evaluate the clinical specificity and sensitivity of 
HE4 and its benefits as a serum marker for EC. 
Matriptase (MT-SP1)
The type II transmembrane serine protease (TTSP) family 
has recently gained increased interest because of their link 
and potential to enhance the aggressive nature of cancer 
cells [31]. The matriptase, a subfamily of TTSP, which is nor-
mally expressed by cells of epithelial origin, is suggested to 
be involved in the degradation of the extracellular matrix 
(ECM), including interstitial basement membrane (BM) in 
certain tumor entities. Therefore, high levels of matriptase 
will in many cases be correlated with poor clinical outcome 
[31, 32]. Matriptase, originally isolated from breast cancer 
cells, is thought to have a pleotropic function where its 
carcinogenetic properties are to facilitate cellular invasion 
and activation of oncogenic pathways [32]. Protease is func-
tionally involved in tumor growth and spread in a variety of 
benign and malignant tumors where its overexpression is 
confirmed in a large number of studies.
Nakamura et al. studied matriptase in association to hu-
man EC assessed by immunohistochemistry for evaluation 
of epithelial cells [33]. The expression level was compared 
in normal endometrium, endometrial hyperplasia and in 
EC tissue respectively. The immunostaining patterns of 
matriptase were then classified into strong, moderate, and 
weak cell staining. EC showed the strongest expression in 
comparison to normal and endometrial hyperplasia. It was 
concluded that matriptase elevation was associated with 
clinicopathological parameters such as advanced stage, 
high grade, myometrial invasion depth, cervical involve-
ment, lymph node metastasis, lymph vascular space involve-
ment and peritoneal cytology. Strong matriptase expression 
is therefore linked to an overall lower survival rate [30–33]. 
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Furthermore, matriptase is showed to be effective in pre-
vention of tumor growth and metastasis formation, which 
makes it both a potential new target for anti-cancer therapy 
as well as a novel prognostic diagnostic marker in several 
cancer types including EC [32].
CONCLUSIONS
The increase in incidence of EC raises the need for dis-
covery of more convenient methods that may contribute to 
early detection and better prognostic assessment. A panel 
of new genes and proteins have therefore been intensively 
studied during the past decade. Some of which are afore-
mentioned in this paper have aroused considerable atten-
tion making them promising in future clinical application. 
However, each biomarker provides only limited information 
and the search for biomarkers with higher sensitivity and 
specificity is required for screening, diagnosis, prognosis, 
and individualized therapy.
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